Target- |
Mechanism- |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date01 Apr 1979 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CA |
First Approval Date31 Dec 1951 |
A Phase 2a double blind, randomised, placebo controlled, two dose study to determine the effect of orally administered methylnaltrexone (MNTX) in preventing post-operative opiate induced constipation in patients undergoing elective orthopaedic surgery - Coated MNTX
A Phase IV, Multi-centre, Double-blind, Randomised, Placebo-controlled Parallel Group Study to Compare the Efficacy and Safety of MOVICOL® with Placebo in Patients with Constipation Associated with Irritable Bowel Syndrome (IBS)
100 Clinical Results associated with Norgine Pharmaceuticals Ltd.
0 Patents (Medical) associated with Norgine Pharmaceuticals Ltd.
100 Deals associated with Norgine Pharmaceuticals Ltd.
100 Translational Medicine associated with Norgine Pharmaceuticals Ltd.